<DOC>
	<DOCNO>NCT00874107</DOCNO>
	<brief_summary>The Phase 2 study describe protocol serve evaluate antitumor activity , safety pharmacokinetic profile Imprime PGG combine bevacizumab concomitant paclitaxel carboplatin therapy patient previously untreated advanced NSCLC . Additionally , study provide guidance design definitive efficacy study Imprime PGG NSCLC patient .</brief_summary>
	<brief_title>Efficacy/Safety Imprime PGG® Injection With Bevacizumab Paclitaxel/Carboplatin Patients With Untreated Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Has read , understood sign informed consent form ( ICF ) approve Independent Review Board/Ethics Committee ( IRB/EC ) ; 2 . Is ages 18 75 year old , inclusive ; 3 . Has histologically cytologically confirm stage IIIB ( malignant pericardial pleural effusion ) stage IV nonsmall cell lung cancer ; 4 . Has nonsquamous , nonsmall cell lung cancer 5 . Has measurable disease , define least one tumor fulfill criterion target lesion accord RECIST ; 6 . Has ECOG performance status 0 1 ; 7 . Has life expectancy &gt; 3 month ; 8 . Has adequate hematologic function evidence : 1 . ANC ≥ 1,500/μL 2 . PLT ≥ 100,000/μL 3 . HGB ≥ 9 g/dL obtain within 1 week prior first dose study medication ; 9 . Has adequate renal function evidence : 1 . Serum creatinine ≤ 1.5 X upper limit normal ( ULN ) reference lab 2 . Urine dipstick proteinuria &lt; 1+ ( i.e. , either 0 trace ) within 2 week Day 1 If urine dipstick ≥ 1+ , urine protein excretion must ≤ 500 mg 24 hour collection obtain within 1 week prior first dose study medication ; 10 . Has adequate hepatic function evidence : 1 . Serum total bilirubin ≤ 1.0 mg/dL 2 . AST ≤ 2.5X ULN reference lab ( ≤ 5X ULN subject know hepatic metastasis ) 3 . ALT ≤ 2.5X ULN reference lab ( ≤ 5X ULN subject know hepatic metastasis ) obtain within 1 week prior first dose study medication ; 11 . Has adequate coagulation function evidence : 1 . INR ≤ 1.5 2 . PTT ≤ ULN reference lab obtain within 1 week prior first dose study medication ; 12 . If woman childbearing potential fertile man ( partner ) , must agree use effective form contraception ( hormonal contraceptive , doublebarrier method abstinence ) study . 1 . Has receive prior systemic chemotherapy time lung cancer ; 2 . Has receive previous radiation therapy &gt; 30 % active bone marrow radiation therapy within 3 week Day 1 ; 3 . Has know hypersensitivity baker 's yeast , active yeast infection ; 4 . Has previous exposure Betafectin® Imprime PGG ; 5 . Has active infection ; 6 . Presents follow medical diagnoses/conditions time screening : 1 . Central nervous system ( CNS ) metastases 2 . Uncontrolled hypertension ( &gt; 150/100 mmHg ) hypertension require &gt; two agent adequate control 3 . Peripheral neuropathy ≥ grade 2 cause 4 . Fever &gt; 38.5° C within 3 day prior screen Day 1 , initial dose 5 . Known HIV/AIDs , Hepatitis B , Hepatitis C , connective tissue autoimmune disease , clinical diagnosis , ongoing intercurrent illness physician 's opinion could interfere participation 7 . Has history follow medical diagnoses/conditions : 1 . Arterial venous thromboembolic hemorrhagic disorder include stroke , transient ischemic attack cerebral infarction 2 . Deep vein thrombosis within 1 year prior screen 3 . Myocardial infarction unstable uncontrolled disease condition relate impacting cardiac function ( e.g. , unstable angina , congestive heart failure ) within previous 6 month 4 . Second malignancy within previous 5 year , basal cell carcinoma , cervical intraepithelial neoplasia curatively treated prostate cancer PSA &lt; 2.0 ng/mL 8 . Has know hypersensitivity bevacizumab , murine protein , component bevacizumab ; 9 . Has know sensitivity polyethoxylated castor oil ; 10 . Has previously receive treatment bevacizumab ; 11 . Has surgery within 4 week Day 1 needle open biopsy within 1 week Day 1 ; 12 . Has nonhealing wound gastric ulcer ; 13 . Has nonhealed bone fracture ; 14 . Is receive systemic anticoagulation therapy ( e.g. , dipyridalmole ( Persantine® ) , ticlopidine ( Ticlid® ) , clopidogrel ( Plavix® ) /or cilostazol ( Pletal® ) ; 15 . Is receive chronic daily treatment aspirin ( &gt; 100 mg/day ) nonsteroidal antiinflammatory agent know inhibit platelet function within 1 week Day 1 ; 16 . Presents follow medical diagnoses/conditions time screening : a. Predominant squamous cell histology 17 . Has history follow medical diagnoses/conditions : 1 . Hemoptysis ( ≥ ½ tsp red blood ) 2 . Bleeding diathesis coagulopathy 18 . If female , pregnant breastfeeding ; 19 . Is receive concurrent investigational therapy receive investigational therapy within period 30 day prior first schedule day dose ( investigational therapy define treatment currently regulatoryauthorityapproved indication ) ; 20 . Has previously receive organ progenitor/stem cell transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Phase 2</keyword>
	<keyword>Randomized</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Imprime PGG</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>